Table 1. Clinical information of the trials for the immunotherapy.

Reference	Tumor characteristics	Patients No (control)	Regimens (per arm)	Immune cell regimens	Culture of immune cell
Zhao 2006	HCC	33(31)	TACE+RFA+CIK,TACE+RFA	1.1–1.5×1010/course	CM,CD3MeAb,IL-2,INF-r,IL-1a.
Hao 2006	HCC	21(46)	TACE+CIK,TACE	1–5×1010/course	CM, IFN-r, CD3McAb, IL-1a, IL-2.
Zhang 2006	HCC	52(92)	TACE+CIK/TACE+PEI+CIK,TACE/TACE+PEI	1.0–1.2×1010/course	CM, IFN-r, CD3McAb, IL-1a, IL-2.
Shi 2007	HCC	38(214)	TACE+CIK,TACE/TACE+PEI	1.0–1.2×1010/course	CM, IFN-r, CD3McAb, IL-1a, IL-2.
Huang 2007	Primary HCC	55(30)	TACE+RFA+CIK,TACE+RFA
Weng 2008	HCC	45(40)	TACE+RFA+CIK,TACE+RFA	1.0–2.0×1010/course	CM,IFN-r,CD3 McAb,IL-1a,IL-2.
Hao 2010	HCC	74(72)	TACE+CIK,TACE	1–5×1010/course	Serum-free culture medium,IFN-r,CD3 McAb,IL-1a,IL-2.
Pan 2010	HCC	42(39)	TACE+RFA+CIK,TACE+RFA	Once every week, at least 4 infusions, more than 1×1010 cells per course.
Wu 2012	Primary HCC	32(38)	TACE+DC-CIK,TACE
Wang 2012	HCC	38(38)	TACE+RFA+CIK,TACE+RFA	Once every twice weeks, at least 3 infusions,1–1.5×1010 cells per course.	IFN-r,CD3 McAb, IL-1a,IL-2.
He 2012	Primary liver cancer	60(58)	TACE+CIK,TACE	1 week after TACE
Huang 2013	HCC	85(89)	TACE+RFA+CIK,TACE+RFA	2 weeks after sequential TACE and RFA, the median successive number of CIK cell infusions was 9 (range, 4–25).	IFN-r, CD3-McAb, IL-2, IL-1a.
Deng 2013	HCC	20(21)	TACE+RFA+CIK,TACE+RFA
Tong 2013	Primary liver cancer	20(18)	TACE+ CIK,TACE	1–5×1010/course	IFN-r, CD3-McAb, IL-2
Xu 2013	Large HCC	40(40)	TACE+PMCT+DC-CIK,TACE+PMCT
Guo 2014	Primary liver cancer	30(38)	TACE+DC-CIK,TACE	1.0×1010/course	AIM-V serum-free culture medium, IFN-r,rhIL-2,CD3 McAb,IL-1,GM-CSF,rhIL-4,TNF-a.
Zhang 2014	liver cancer	41(44)	TACE+RFA+DC-CIK,TACE+RFA	6 times 7 days after TACE and RFA, and the number of DC-CIK cells was above 1.0×1010
Liu 2014	Advanced HCC	23(17)	TACE+DC-CIK,TACE
Cheng 2014	liver cancer	32(28)	TACE+DC-CIK,TACE	4 infusions of DC-CIK cells	IFN-r, CD3-McAb, IL-2, IL-1a, GM-CSF, IL-4, HSP.